Patent ID: 9259397
Filing Date: 2016-02-16
CPC Classification: A61K,A61P

Claim Text:
1. A method of effectively treating seasonal allergic rhinitus, chronic idiopathic urticaria, or both conditions in a human patient, comprising administering loratadine transdermally to the human patient by applying a transdermal delivery system comprising (i) an active agent consisting of loratadine or a pharmaceutically acceptable salt thereof, (ii) a polymer, (iii) a softening agent; and (iv) a solvent, to the skin of a patient, and maintaining said transdermal delivery system in contact with the skin of the patient for at least 5 days, said transdermal delivery system maintaining an effective mean relative release rate to provide a therapeutic blood level of said loratadine within three days from the initiation of the dosing interval, and thereafter maintaining a therapeutic blood level until the end of at least the five-day dosing interval, said transdermal delivery device maintaining a plasma level of loratadine at steady state of about 3 ng/ml; said transdermal delivery system having a mean relative release rate of from about 2.8 μg/cm from about 2.3 μg/cm from about 2.0 μg/cm and a mean relative release rate of from about 1.8 μg/cm